NasdaqGM:ARDXBiotechs
Ardelyx (ARDX) Faces A Valuation Test, Is The Discount Too Wide?
Why Ardelyx Stock Is Back in Focus
Ardelyx (ARDX) is drawing fresh attention after recent market activity around its kidney disease and irritable bowel syndrome treatments, putting the stock under closer review for how the business fundamentals line up.
See our latest analysis for Ardelyx.
At a share price of US$5.03, Ardelyx has seen short term share price pressure, with the 30 day share price return down 9.37% and the year to date share price return down 18.21%. At the same time, the 1 year...